1. Bufexamac products require reclassification; unfavourable risk-benefit

   News item 31 July 2021 Pages: 1 - 1

2. EMA assessing safety of anakinra in adults with COVID-19

   News item 31 July 2021 Pages: 2 - 2

3. FDA removes strongest warning against statin use in pregnancy

   News item 31 July 2021 Pages: 3 - 3

4. PMDA: precautions should be revised for Covid-19 vaccine

   News item 31 July 2021 Pages: 4 - 4

5. Association between DPP-4 inhibitors and bullous pemphigoid in US

   Clinical study 31 July 2021 Pages: 5 - 5

6. Dolutegravir-related obesity increases adverse pregnancy outcomes

   Clinical study 31 July 2021 Pages: 6 - 6

7. Drug interactions with anticoagulants increase risk of events

   Clinical study 31 July 2021 Pages: 7 - 7

8. IL17 inhibitors do not increase risk of IBD versus etanercept

   Clinical study 31 July 2021 Pages: 8 - 8

9. Methadone increases cardiac repolarisation instability

   Clinical study 31 July 2021 Pages: 9 - 9

10. Vitamin D supplementation improves statin-related myopathy

    Clinical study 31 July 2021 Pages: 10 - 10

11. Other adverse reaction research

    News item 31 July 2021 Pages: 11 - 11

12. Abemaciclib

    Case report 31 July 2021 Pages: 12 - 12

13. Aciclovir

    Case report 31 July 2021 Pages: 13 - 13

14. Ad26.cov2-s/azd-1222/covid-19-vaccine-pfizer-biontech

    Case report 31 July 2021 Pages: 14 - 14

15. Ad26.COV2-S/COVID-19-Vaccine-Pfizer-BioNTech

    Case report 31 July 2021 Pages: 15 - 15

16. Adalimumab

    Case report 31 July 2021 Pages: 16 - 16

17. Adalimumab/naproxen

    Case report 31 July 2021 Pages: 17 - 17

18. Adapalene

    Case report 31 July 2021 Pages: 18 - 18

19. Adefovir-dipivoxil

    Case report 31 July 2021 Pages: 19 - 19

20. Afatinib

    Case report 31 July 2021 Pages: 20 - 20

21. Afatinib/osimertinib

    Case report 31 July 2021 Pages: 21 - 21

22. Alectinib

    Case report 31 July 2021 Pages: 22 - 22

23. Alectinib

    Case report 31 July 2021 Pages: 23 - 23

24. Alectinib/bosutinib/osimertinib

    Case report 31 July 2021 Pages: 24 - 24

25. Alendronic-acid/colecalciferol/amoxicillin/clavulanic-acid

    Case report 31 July 2021 Pages: 25 - 25

26. Alendronic-acid/levofloxacin/zoledronic-acid

    Case report 31 July 2021 Pages: 26 - 26

27. Alglucosidase-alfa

    Case report 31 July 2021 Pages: 27 - 27

28. Allopurinol

    Case report 31 July 2021 Pages: 28 - 28

29. Alpelisib

    Case report 31 July 2021 Pages: 29 - 29

30. Alpelisib

    Case report 31 July 2021 Pages: 30 - 30

31. Alprazolam/fentanyl

    Case report 31 July 2021 Pages: 31 - 31

32. Alteplase/heparin/rivaroxaban

    Case report 31 July 2021 Pages: 32 - 32

33. Amantadine

    Case report 31 July 2021 Pages: 33 - 33

34. Amiodarone

    Case report 31 July 2021 Pages: 34 - 34

35. Amisulpride/clozapine/olanzapine

    Case report 31 July 2021 Pages: 35 - 35

36. Amitriptyline/mirtazapine/venlafaxine

    Case report 31 July 2021 Pages: 36 - 36

37. Amoxicillin/amoxicillin/clavulanic-acid

    Case report 31 July 2021 Pages: 37 - 37

38. Amphotericin-B liposomal

    Case report 31 July 2021 Pages: 38 - 38

39. Antibacterials/dexamethasone

    Case report 31 July 2021 Pages: 39 - 39

40. Antibacterials/ethambutol

    Case report 31 July 2021 Pages: 40 - 40

41. Antibacterials/methylprednisolone

    Case report 31 July 2021 Pages: 41 - 41

42. Antiepileptic drugs

    Case report 31 July 2021 Pages: 42 - 42

43. Antihyperglycaemics/Immunosuppressants

    Case report 31 July 2021 Pages: 43 - 43

44. Antineoplastics

    Case report 31 July 2021 Pages: 44 - 44

45. Antineoplastics

    Case report 31 July 2021 Pages: 45 - 45

46. Antineoplastics

    Case report 31 July 2021 Pages: 46 - 46

47. Antineoplastics

    Case report 31 July 2021 Pages: 47 - 47

48. Antineoplastics

    Case report 31 July 2021 Pages: 48 - 48

49. Antineoplastics

    Case report 31 July 2021 Pages: 49 - 49

50. Antineoplastics

    Case report 31 July 2021 Pages: 50 - 50